Higher dose requirements with insulin detemir in type 2 diabetes--three cases and a review of the literature

Diabetes Res Clin Pract. 2009 May;84(2):e24-6. doi: 10.1016/j.diabres.2009.02.009. Epub 2009 Feb 28.

Abstract

We report on three type 2 diabetic patients whose daily basal insulin dose requirements were substantially reduced after switching from insulin detemir to insulin glargine. Meta-analysis of three randomised trials of basal insulin initiation confirmed this increased insulin detemir dose requirement in type 2 patients. Potential explanations are discussed.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dose-Response Relationship, Drug
  • Female
  • Glycated Hemoglobin A / metabolism
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / analogs & derivatives*
  • Insulin / therapeutic use
  • Insulin Detemir
  • Insulin Glargine
  • Insulin, Long-Acting
  • Male
  • Meta-Analysis as Topic
  • Middle Aged
  • Randomized Controlled Trials as Topic
  • Weight Gain

Substances

  • Blood Glucose
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Insulin
  • Insulin, Long-Acting
  • Insulin Glargine
  • Insulin Detemir